Unmet Needs in Advanced or Metastatic TRK Fusion-Positive Thyroid Cancer

Video

Marie E. Cabanillas, MD, discusses current unmet needs in advanced or metastatic TRK fusion-positive thyroid cancer.

Marie E. Cabanillas, MD, an oncologic endocrinologist at the University of Texas MD Anderson Cancer Center, discusses current unmet needs in advanced or metastatic TRK fusion-positive thyroid cancer.

According to Cabanillas, more options for RET, ALK, and BRAF mutations exist. TRK mutations are another rare fusion requiring an inhibitor. Additionally, there are limitations on the 2 currently approved therapies, sorafenib (Nexavar) and lenvatinib (Lenvima).

For some patients, these therapies are too dangerous, according to Cabanillas. For patients who have a predisposition for bleeding, especially bleeding from the tumor VEGF inhibitors may be unsafe as they may increase bleeding risk. There is a need for more tolerable therapies for this patient population.

Related Videos
Marcia S. Brose, MD, PhD, an expert on thyroid cancer
Marcia S. Brose, MD, PhD, an expert on thyroid cancer
Marcia S. Brose, MD, PhD, an expert on thyroid cancer
Marcia S. Brose, MD, PhD, an expert on thyroid cancer
Marcia S. Brose, MD, PhD, an expert on thyroid cancer
Marcia S. Brose, MD, PhD, an expert on thyroid cancer
Marcia S. Brose, MD, PhD, an expert on thyroid cancer
Related Content